Under prospective screening, 21.8% of adult stem cell transplant recipients develop severe thrombotic microangiopathy within a hundred days.1

Their non-relapse mortality is 42%, against 5.8% among those who do not.2

One in five transplant recipients meets a complication that kills nearly half of them. We intend to make that statistic historical.

Please note: Casvira Bio operates in a stealth capacity.

Messages arrive with the people doing the work. We keep your details for correspondence and no other purpose. Privacy.